Development of an in-house 188W/188Re generator for rhenium-188 production and radiolabelling studies

Diana Melis, Tomas Opsomer, Bernard Ponsard, Andrew Burgoyne, Gilles Gasser, Michiel Van de Voorde, Maarten Ooms

Research outputpeer-review


Rhenium is a fascinating metal with a rich coordination chemistry and its isotopes have shown great potential for use in radiotherapy. The isotope 188Re is particularly interesting as it emits high-energy beta particles (Emax = 2.12 MeV), making it perfect for radiotherapy of large tumours. The short half-life (t1/2 = 16.9 h) of rhenium-188 also allows it to be used in targeted radionuclide therapy when linked to peptides or antibodies. Additionally, rhenium-188 also decays with a 155 keV (15%) gamma emission suitable for imaging and dosimetry, making it rhenium-188 an ideal theranostic agent in clinical nuclear medicine. Rhenium-188 is readily available from a 188W/188Re generator, which enables the use of non-carrier added (nca) rhenium- 188 in hospitals and remote locations. In light of the recent shortage of 188W/188Re generators on the market, we undertook efforts to prepare our own generator to provide a constant rhenium-188 supply for our research into 188Re-based radiopharmaceuticals. Here we present the in-house development of the 188W/188Re generator and the first applications of this rhenium-188 in the development of novel 188Re-chelators.
Original languageEnglish
Title of host publicationNuclear Medicine and Biology
Subtitle of host publicationAbstracts of the Fourth International Symposium on Technetium and Other Radiometals in Chemistry and Medicine (TERACHEM 2022)
Number of pages1
StatePublished - Dec 2022
Event2022 - TERACHEM: The Fourth International Symposium on Technetium and Other Radiometals in Chemistry and Medicine - Bressanone
Duration: 14 Sep 202217 Sep 2022

Publication series

NameNuclear Medicine and Biology
ISSN (Print)0969-8051
ISSN (Electronic)1872-9614


Conference2022 - TERACHEM

Cite this